<?xml version="1.0" encoding="UTF-8"?>
<p id="p0120">Two double-blinded placebo-controlled trials are also recruiting in Hubei Province, China [
 <xref rid="bb0220" ref-type="bibr">44</xref>,
 <xref rid="bb0225" ref-type="bibr">45</xref>]. One targets hospitalized patients with mild-to-moderate COVID-19 [
 <xref rid="bb0220" ref-type="bibr">44</xref>], while the other is focused on severe cases [
 <xref rid="bb0225" ref-type="bibr">45</xref>]. The primary outcome measure for the study on mild or moderate cases is time to clinical recovery, as defined by normalization of body temperature, respiratory rate, and oxygen saturation, and the resolution of cough for at least 72Â h [
 <xref rid="bb0220" ref-type="bibr">44</xref>]. In the study on severe cases, time to clinical improvement is the primary outcome and is defined using a six-category scale, ranging from discharge to death [
 <xref rid="bb0225" ref-type="bibr">45</xref>].
</p>
